Studies with oral lorazepam in anxiety neurosis associated with depressive symptomatology.
Twelve studies were undertaken under a common four-week protocol to investigate the efficacy of lorazepam compared with placebo in reducing the severity of moderate to severe anxiety in 264 patients also having significant depressive symptomatology. Analysis of the results indicated that lorazepam gave generally better anxiety relief than placebo; in the majority of comparisons the differences were substantial enough to be both statistically and clinically significant. No data were obtained evidencing significant toxicity in either treatment group.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000008:administration & dosage*; D001008:Anxiety Disorders / Q000188:drug therapy*; D003863:Depression / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D013997:Time Factors
D014151:Anti-Anxiety Agents; D010919:Placebos; D008140:Lorazepam